首页> 美国卫生研究院文献>Oncology Letters >Expression of miRNA-146b-5p in patients with thyroid cancer in combination with Hashimotos disease and its clinical significance
【2h】

Expression of miRNA-146b-5p in patients with thyroid cancer in combination with Hashimotos disease and its clinical significance

机译:miRNA-146b-5p在甲状腺癌合并桥本病患者中的表达及其临床意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The expression level of microRNA (miRNA)-146b in patients with thyroid carcinoma (TC) in combination with Hashimoto's thyroditis (HT) was evaluated to analyze the clinical significance. Eighty-seven patients who underwent thyroid surgery in The Third Affiliated Hospital of Southern Medical University from March 2010 to February 2013 were enrolled. Of the patients, 37 were diagnosed with TC (group A), and 50 were diagnosed with TC in combination with HT (group B). Forty patients were diagnosed with HT (group C). The expression levels of miRNA-146b-5p in cancer tissue and paracancerous tissue of patients in the two groups were measured by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Correlation between the miRNA-146b-5p levels and the clinicopathological characteristics of patients with combined TC and HT were evaluated. According to the expression of miRNA-146b-5p, patients in group B were separated into the high and low expression groups to observe the five-year cancer recurrence rate. There was no significant difference in miRNA-146b-5p expression between the papillary carcinoma group, the follicular carcinoma group and the medullary carcinoma group (P>0.05). The miRNA-146b-5p expression in the lesion tissue of group B was significantly higher than that of groups A and C, while the miRNA-146b-5p expression in the lesion tissue of group A was significantly higher than that of group C (P<0.05), and the lesion tissue of the three groups was higher than that of the corresponding parastatal tissue (P<0.05). The miRNA-146b-5p expression level was associated with tumor size, lymph node metastasis and TNM stage (P<0.05), while not associated with sex, age, lesion multiplicity, smoking history, diabetes history and pathological type in group B (P>0.05). The non-recurrence rate of group B high expression subgroup was lower than that of group B low expression subgroup (P=0.045). High expression of miRNA-146b-5p was found in the cancer tissues of patients with combined TC and HT. The expression level of miRNA-146b-5p was associated with tumor size, lymph node metastasis and TNM stage. It is a potential prognostic indicator for patients with combined TC and HT.
机译:评估甲状腺癌(TC)合并桥本甲状腺炎(HT)患者中microRNA(miRNA)-146b的表达水平,以分析其临床意义。纳入2010年3月至2013年2月在南方医科大学第三附属医院接受甲状腺手术的87例患者。在这些患者中,37例被诊断为TC(A组),50例被诊断为TC与HT结合(B组)。 40名患者被诊断患有HT(C组)。采用逆转录定量聚合酶链反应(RT-qPCR)法检测两组患者癌组织和癌旁组织中miRNA-146b-5p的表达水平。评估TC和HT合并患者的miRNA-146b-5p水平与临床病理特征之间的相关性。根据miRNA-146b-5p的表达,将B组患者分为高表达组和低表达组,观察其五年复发率。乳头状癌组,滤泡状癌组和髓样癌组之间的miRNA-146b-5p表达差异无统计学意义(P> 0.05)。 B组病变组织中miRNA-146b-5p表达明显高于A组和C组,而A组病变组织中miRNA-146b-5p表达明显高于C组(P <0.05),且三组病变组织均高于相应的半椎旁组织(P <0.05)。 B组miRNA-146b-5p表达水平与肿瘤大小,淋巴结转移和TNM分期有关(P <0.05),而与性别,年龄,病灶多样性,吸烟史,糖尿病史和病理类型无关(P > 0.05)。 B组高表达亚组的非复发率低于B组低表达亚组(P = 0.045)。在合并了TC和HT的患者的癌组织中发现了miRNA-146b-5p的高表达。 miRNA-146b-5p的表达水平与肿瘤大小,淋巴结转移和TNM分期有关。它是合并TC和HT的患者的潜在预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号